Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

Introduction

• Org Study ID: 2024-0919
• NTC ID: NCT06601296
• Lead Sponsor Name: University of Texas Southwestern Medical Center
• Status: RECRUITING

Conditions

• Renal Cell Carcinoma

Brief Summary

To evaluate progression of metastatic renal cell carcinoma from the initiation of PULSAR radiotherapy in combination with IMSA101 injectable onward.

Eligibility Criteria

Inclusion Criteria:

* Patients must have metastatic ccRCC.
* Patients must have oligoprogression defined as progression in ≤3 lesions.
* All oligoprogression lesions must be suitable for radiation.
* Patients must have at least one site of disease that can be safely injected with IMSA101. Lung metastases are excluded.
* ECOG performance status 0-2.
* Age ≥ 18 years.
* Patients must have adequate organ and marrow function within 14 days prior to study entry.
* All IMDC risk categories are allowed.

Exclusion Criteria:

* Patients with progressive ultracentral/central chest lesions will be excluded